- Victim Assistance
- Consumer Protection
- Media Center
- Topical Index
MADISON - Attorney General J.B. Van Hollen announced today that Wisconsin has joined with other states and the federal government and reached an agreement in principle with AstraZeneca Pharmaceuticals LP, to settle allegations it engaged in an off-label marketing campaign that improperly promoted the antipsychotic drug, Seroquel. AstraZeneca will pay the states and the federal government a total of $520 million in damages and penalties to compensate Medicaid and various federal healthcare programs for harm suffered as a result of this conduct.
Van Hollen explained that the agreement calls for payment of $4,420,111.62 to the state as its portion of the $9,936,461.78 attributable to Wisconsin Medicaid, a medical assistance program for the needy jointly funded by the state and federal governments. The remaining $5,516,349.96 will be paid to the federal government.
"This agreement again highlights the priority my office places on protection of the public treasury. Taxpayers should know that their dollars are being put to good use for much needed services, not to enrich those who would exploit limited government resources," said Van Hollen.
Seroquel is one of a newer generation of antipsychotic medications (called atypical antipsychotics) used to treat certain psychological disorders. From January 1, 2001 through December 31, 2006, AstraZeneca promoted the sale and use of Seroquel for certain uses that the Food and Drug Administration had not approved. The settlement resolves a government investigation into promotional activities undertaken by AstraZeneca that were directed not only to psychiatrists but also to primary care physicians and other health care professionals for unapproved uses in the treatment of medical conditions such as aggression, Alzheimer's disorder, anger management, anxiety, attention deficit hyperactivity disorder, dementia and sleeplessness.
In implementing its marketing campaign, AstraZeneca was also alleged to have made illegal payments to physicians, paying their way to travel to resort locations to "advise" AstraZeneca about marketing messages for unapproved uses, to serve as authors of articles written by AstraZeneca and its agents, and to conduct studies for unapproved uses of Seroquel. The settlement resolves claims that, as a result of these promotional activities, AstraZeneca caused physicians to prescribe Seroquel for children, adolescents and dementia patients in long term care facilities, which are uses that were not medically accepted indications for which state Medicaid programs would approve reimbursement.
As part of the settlement, AstraZeneca will enter into a Corporate Integrity Agreement with the United States Department of Health and Human Services, Office of the Inspector General, which will closely monitor the company's future marketing and sales practices.
This settlement is based on two qui tam cases that were filed in the United States District Court for the Eastern District of Pennsylvania by relators - private parties who filed actions under state and federal false claims statutes. Wisconsin was named as a co-plaintiff state in one of the actions.
A National Association of Medicaid Fraud Control Units team participated in the investigation and conducted the settlement negotiations with AstraZeneca on behalf of the settling states.